Creating new anticancer drugs is a billion dollar investment. By working with StemTek, pharmaceutical companies can save time and resources by outsourcing early drug discovery to our experienced R&D team.
Our value-added research services using Cell2Sphere™ technology offer rigorous analysis to profile compounds for their effect on cancer stem cell populations.
We specialize in early stage compound validation using 3D spheroid models to measure anti-cancer stem cell activity, from primary HTS screening to secondary validation, hit to lead assessment, lead optimization validation, fresh human tumor validation to in vivo efficacy studies.
Using Cell2Sphere™ technology.
In vitro efficacy compound profiling.
Modified Xenograft models to assess tumor initiation.
Increased physiological relevance for compound profiling.